Literature DB >> 22298772

Age-related changes in rat myocardium involve altered capacities of glycosaminoglycans to potentiate growth factor functions and heparan sulfate-altered sulfation.

Minh Bao Huynh1, Christophe Morin, Gilles Carpentier, Stephanie Garcia-Filipe, Sofia Talhas-Perret, Véronique Barbier-Chassefière, Toin H van Kuppevelt, Isabelle Martelly, Patricia Albanese, Dulce Papy-Garcia.   

Abstract

Glycosaminoglycans (GAGs) are essential components of the extracellular matrix, the natural environment from which cell behavior is regulated by a number or tissue homeostasis guarantors including growth factors. Because most heparin-binding growth factor activities are regulated by GAGs, structural and functional alterations of these polysaccharides may consequently affect the integrity of tissues during critical physiological and pathological processes. Here, we investigated whether the aging process can induce changes in the myocardial GAG composition in rats and whether these changes can affect the activities of particular heparin-binding growth factors known to sustain cardiac tissue integrity. Our results showed an age-dependent increase of GAG levels in the left ventricle. Biochemical and immunohistological studies pointed out heparan sulfates (HS) as the GAG species that increased with age. ELISA-based competition assays showed altered capacities of the aged myocardial GAGs to bind FGF-1, FGF-2, and VEGF but not HB EGF. Mitogenic assays in cultured cells showed an age-dependent decrease of the elderly GAG capacities to potentiate FGF-2 whereas the potentiating effect on VEGF(165) was increased, as confirmed by augmented angiogenic cell proliferation in Matrigel plugs. Moreover, HS disaccharide analysis showed considerably altered 6-O-sulfation with modest changes in N- and 2-O-sulfations. Together, these findings suggest a physiological significance of HS structural and functional alterations during aging. This can be associated with an age-dependent decline of the extracellular matrix capacity to efficiently modulate not only the activity of resident or therapeutic growth factors but also the homing of resident or therapeutic cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298772      PMCID: PMC3322837          DOI: 10.1074/jbc.M111.335901

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Characterization of the human sulfatase Sulf1 and its high affinity heparin/heparan sulfate interaction domain.

Authors:  Marc-André Frese; Fabian Milz; Marina Dick; William C Lamanna; Thomas Dierks
Journal:  J Biol Chem       Date:  2009-08-07       Impact factor: 5.157

2.  The heparan sulfate motif (GlcNS6S-IdoA2S)3, common in heparin, has a strict topography and is involved in cell behavior and disease.

Authors:  Nicole C Smits; Sindhulakshmi Kurup; Angelique L Rops; Gerdy B ten Dam; Leon F Massuger; Theo Hafmans; Jeremy E Turnbull; Dorothe Spillmann; Jin-ping Li; Stephen J Kennel; Jonathan S Wall; Nicholas W Shworak; P N Richard Dekhuijzen; Johan van der Vlag; Toin H van Kuppevelt
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

Review 3.  Gene therapy for ischemic heart disease.

Authors:  Madhav Lavu; Susheel Gundewar; David J Lefer
Journal:  J Mol Cell Cardiol       Date:  2010-06-26       Impact factor: 5.000

Review 4.  Proteomics: a reality-check for putative stem cells.

Authors:  Marianna Prokopi; Manuel Mayr
Journal:  Circ Res       Date:  2011-02-18       Impact factor: 17.367

Review 5.  FGF-1: from biology through engineering to potential medical applications.

Authors:  Malgorzata Zakrzewska; Ewa Marcinkowska; Antoni Wiedlocha
Journal:  Crit Rev Clin Lab Sci       Date:  2008       Impact factor: 6.250

Review 6.  Cardiovascular gene therapy: current status and therapeutic potential.

Authors:  M M Gaffney; S O Hynes; F Barry; T O'Brien
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

Review 7.  Glycosaminoglycans and proteoglycans: overlooked entities?

Authors:  Susan Yung; Tak Mao Chan
Journal:  Perit Dial Int       Date:  2007-06       Impact factor: 1.756

Review 8.  Fibroblast growth factor-2 and cardioprotection.

Authors:  Elissavet Kardami; Karen Detillieux; Xin Ma; Zhisheng Jiang; Jon-Jon Santiago; Sarah K Jimenez; Peter A Cattini
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

9.  Dermatan sulfate domains defined by the novel antibody GD3A12, in normal tissues and ovarian adenocarcinomas.

Authors:  Gerdy B Ten Dam; Shuhei Yamada; Fumi Kobayashi; Anurag Purushothaman; Els M A van de Westerlo; Johan Bulten; Anders Malmström; Kazuyuki Sugahara; Leon F Massuger; Toin H van Kuppevelt
Journal:  Histochem Cell Biol       Date:  2009-04-10       Impact factor: 4.304

10.  Characterization of anticoagulant heparinoids by immunoprofiling.

Authors:  Tessa J Wijnhoven; Els M van de Westerlo; Nicole C Smits; Joost F Lensen; Angelique L Rops; Johan van der Vlag; Jo H Berden; Lambert P van den Heuvel; Toin H van Kuppevelt
Journal:  Glycoconj J       Date:  2007-10-02       Impact factor: 2.916

View more
  17 in total

1.  Fact versus artifact: avoiding erroneous estimates of sulfated glycosaminoglycan content using the dimethylmethylene blue colorimetric assay for tissue-engineered constructs.

Authors:  C H Zheng; M E Levenston
Journal:  Eur Cell Mater       Date:  2015-04-19       Impact factor: 3.942

Review 2.  The "in and out" of glucosamine 6-O-sulfation: the 6th sense of heparan sulfate.

Authors:  Rana El Masri; Amal Seffouh; Hugues Lortat-Jacob; Romain R Vivès
Journal:  Glycoconj J       Date:  2016-11-03       Impact factor: 2.916

3.  Structural characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase protofibrils preventing α-synuclein oligomeric species toxicity.

Authors:  César L Ávila; Clarisa M Torres-Bugeau; Leandro R S Barbosa; Elisa Morandé Sales; Mohand O Ouidja; Sergio B Socías; M Soledad Celej; Rita Raisman-Vozari; Dulce Papy-Garcia; Rosangela Itri; Rosana N Chehín
Journal:  J Biol Chem       Date:  2014-03-26       Impact factor: 5.157

Review 4.  Heparan sulfate proteoglycans as key regulators of the mesenchymal niche of hematopoietic stem cells.

Authors:  Dulce Papy-Garcia; Patricia Albanese
Journal:  Glycoconj J       Date:  2017-06-02       Impact factor: 2.916

5.  Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosis.

Authors:  Jingning Lu; Linda Auduong; Eric S White; Xinping Yue
Journal:  Am J Respir Cell Mol Biol       Date:  2014-01       Impact factor: 6.914

Review 6.  Effect of Polarization and Chronic Inflammation on Macrophage Expression of Heparan Sulfate Proteoglycans and Biosynthesis Enzymes.

Authors:  Maarten Swart; Linda Troeberg
Journal:  J Histochem Cytochem       Date:  2018-09-11       Impact factor: 2.479

7.  Cardiac glycosaminoglycans and structural alterations during chronic stress-induced depression-like behavior in mice.

Authors:  Hien Luong; Sarojini Singh; Mallikarjun Patil; Prasanna Krishnamurthy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-04-09       Impact factor: 4.733

8.  New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease.

Authors:  Sonia Lehri-Boufala; Mohand-Ouidir Ouidja; Véronique Barbier-Chassefière; Emilie Hénault; Rita Raisman-Vozari; Laure Garrigue-Antar; Dulce Papy-Garcia; Christophe Morin
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

9.  ChGn-2 Plays a Cardioprotective Role in Heart Failure Caused by Acute Pressure Overload.

Authors:  Andreas Haryono; Koji Ikeda; Dhite Bayu Nugroho; Takehiro Ogata; Yumika Tsuji; Satoaki Matoba; Kensuke Moriwaki; Hiroshi Kitagawa; Michihiro Igarashi; Ken-Ichi Hirata; Noriaki Emoto
Journal:  J Am Heart Assoc       Date:  2022-03-24       Impact factor: 6.106

10.  p38 MAPK signaling underlies a cell-autonomous loss of stem cell self-renewal in skeletal muscle of aged mice.

Authors:  Jennifer D Bernet; Jason D Doles; John K Hall; Kathleen Kelly Tanaka; Thomas A Carter; Bradley B Olwin
Journal:  Nat Med       Date:  2014-02-16       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.